Compare GSK plc (GSK) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Rockwell Automation — how do they compare? GSK plc trades at $51.15 (market cap $102.60B), while Rockwell Automation trades at $446.44 (market cap $49.64B). The key difference: GSK plc is far larger — about 2.1× Rockwell Automation's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | ROK | |
|---|---|---|
Market Cap | $102.60B | $49.64B |
Sector | Health | Industrials |
52-Week High | $61.18 | $495.08 |
52-Week Low | $38.22 | $333.75 |
Enterprise Value | $123.04B | $52.77B |
Dividend Yield | 3.57% | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Rockwell Automation (ROK) trades at $451.86, up 3.82% over 24 hours, with a neutral technical signal. The stock exhibits strong fundamentals, including a 49.09% gross margin and consistent earnings beats, with Q2 2026 EPS of $3.49 surpassing the $3.38 estimate. Recent news highlights AI integration in quality management systems, signaling innovation momentum. Valuation ratios are elevated, with a P/E of 41.85 and P/S of 5.6, reflecting premium pricing.
The outlook remains positive due to robust earnings performance and raised fiscal 2026 guidance, though high valuation multiples and inflation pressures pose risks. Analyst consensus is a Buy with a $507 price target, suggesting 12% upside. Key risks include cost inflation and competitive threats in industrial automation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
